DOI: https://doi.org/10.2298/SARH260608073E
UDC: 616.56-008.8-085

ORIGINAL ARTICLE / ОРИГИНАЛНИ РАД

Can heart rate variability be utilized to predict compensatory sweating after endoscopic thoracic sympathicotomy in patients with primary focal hyperhidrosis?

Ivan Ergelašev[1,2], Ivan Kuhajda[1,2], Stefan Andrić[3], Sanja Ergelašev[3], Aleksandra Vulin[1,3], Siniša Maksimović[1,2], Srđan Gavrilović[1,4], Uroš Batranović[4], Marko Bojović[1,5], Nensi Lalić[1,6]

[1]University of Novi Sad, Faculty of Medicine Novi Sad, Novi Sad, Serbia;
[2]Institute for Pulmonary Diseases of Vojvodina, Thoracic Surgery Clinic, Novi Sad – Sremska Kamenica, Serbia;
[3]Institute for Cardiovascular Diseases of Vojvodina, Clinic for Cardiology, Novi Sad – Sremska Kamenica, Serbia;
[4]Institute for Pulmonary Diseases of Vojvodina, Emergency Pulmonology Clinic, Novi Sad – Sremska Kamenica, Serbia;
[5]Oncology Institute of Vojvodina, Clinic of Radiation Oncology, Novi Sad – Sremska Kamenica, Serbia;
[6]Institute for Pulmonary Diseases of Vojvodina, Clinic for Pulmonary Oncology, Novi Sad – Sremska Kamenica, Serbia

SUMMARY

Introduction/Objective Hyperhidrosis is a condition of pathologically excessive sweating that exceeds the body's physiological requirements for thermoregulation. Endoscopic thoracic sympathicotomy (ETS) is a commonly used treatment for primary focal hyperhidrosis (PFH); however, it may result in compensatory sweating (CS), which represents its most frequent postoperative complication. This study aimed to investigate whether heart rate variability (HRV) parameters could predict CS.

Methods A prospective single-center study was conducted in 100 patients with PFH who underwent ETS. Preoperatively, all patients underwent 24-hour Holter electrocardiographic monitoring to assess standard HRV parameters. ETS was performed by transection of the sympathetic chain at the level of the third (R3) and fourth (R4) ribs, including the accessory Kuntz fibers. One month after surgery, the presence and severity of CS were assessed.

Results CS was absent in 61% of patients ($p = 0.028$). Mild CS was the most common form ($p < 0.01$). No statistically significant differences were observed in the analyzed preoperative HRV parameters between patients with and without CS ($p > 0.05$), including the low-frequency (LF)/high-frequency (HF) ratios, which represent balanced autonomic activity (LF/HF < 2) and sympathetic predominance (LF/HF ≥ 2). Receiver operating characteristic curve analysis showed that age had significant predictive accuracy for CS (area under the curve 0.7333; 95% confidence interval 0.634–0.833; $p < 0.01$), with an optimal cut-off of 23.5 years (sensitivity 0.82, specificity 0.47).

Conclusion HRV parameters cannot reliably predict CS following bilateral ETS in patients with PFH. The study confirmed that the optimal age for surgery is below 23.5 years.

Keywords: video-assisted thoracic surgery; sweating; sympathectomy; autonomic nervous system; minimally invasive surgery

INTRODUCTION

Hyperhidrosis is defined as a condition of pathologically excessive sweating that exceeds the body's physiological needs for thermoregulation. Hyperhidrosis can be secondary, most often generalized, as a consequence of various diseases and conditions, or primary, focal or cryptogenic, with involvement of the palms, soles or axillae. The pathophysiology of primary focal hyperhidrosis (PFH) remains unclear. Excessive sweating in PFH is a direct consequence of increased secretion by sweat glands. Eccrine glands in individuals with PFH are completely normal in anatomy, number, and distribution [1]. It has been suggested that PFH results from complex hyperstimulation of the sympathetic nervous system (SNS) when exposed to emotional stress. Any emotional state or exposure to stress can be an activator of an episode of PFH, but symptoms can also occur without any emotional or thermal stimuli. After the action of an activating stimulus, sweating occurs instantly and is continuous. If conservative treatment fails, endoscopic thoracic sympathicotomy (ETS) is the method of choice [2, 3]. The most common complication of ETS is compensatory sweating (CS) [4]. CS affects regions of the body that have not been previously surgically altered. The mechanism of action is still unknown [5]. Some research also shows a high prevalence of depression and anxiety disorders in this group, along with specific dietary habits, including increased caffeine consumption and the recognition of spicy and fatty foods as sweating triggers [6, 7]. Expert consensus stated that, to prevent CS, patients undergoing surgery should preferably be under

Received • Примљено: June 8, 2026
Accepted • Прихваћено: September 3, 2026
Online first: September 18, 2026

Correspondence to:
Marko BOJOVIĆ
University of Novi Sad
Faculty of Medicine
Hajduk Veljkova 3
21137 Novi Sad
Serbia
marko.bojovic@mf.uns.ac.rs

25 years of age and have a body mass index under 28 [3, 8]. Neuronal cell bodies responsible for the innervation of the sweat glands of the trunk and upper extremities are located at the level of the second to eighth thoracic segments of the spinal cord [9]. With the current evidence level, it is generally accepted that most cardiac sympathetic fibers also originate from the spinal cord at the level of the first to fifth thoracic segments [10, 11].

Heart rate variability (HRV) is a non-invasive, easily reproducible method of measuring the influence of the autonomic nervous system on cardiac function. The data were obtained through 24-hour Holter monitoring and subsequent computer processing. HRV indices provide numerical values of cardiac autonomic nervous system tone. The basic principle of HRV is the measurement of the change in the interval between two consecutive heartbeats – rhythm fluctuations [12]. Research worldwide indicates that patients with hyperhidrosis experience a significant decrease in quality of life. This reduction is reflected in lower scores on the mental component of the SF-36 questionnaire and decreased values on the Dermatology Life Quality Index [13, 14]. However, after treatment of primary hyperhidrosis, the quality of life of patients improves significantly, and this improvement is maintained for many years after the intervention [15, 16]. This is shown by global meta-analyses and observations by domestic authors [17].

The aim of this study was to confirm the potential existence of HRV parameters that would serve as predictors of CS.

METHODS

A prospective, monocentric, non-interventional study was conducted at the Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia, in the period from March 2022 to July 2024. After voluntarily signing the informed consent form, 100 subjects were included in the study. Patients were divided into two equal groups (50 patients each) according to the number of affected regions: palmar and plantar (PP) PFH, and palmar, plantar and axillary (PPA) PFH. Inclusion criteria were: first operation for PFH, Hyperhidrosis Disease Severity Scale grades three and four. Exclusion criteria were the following: psychiatric diseases, cardiac diseases and use of drugs, acute infections, use of alcohol, narcotics and tobacco, professional sports. Holter monitoring for 24 hours was undertaken preoperatively using EVO 4 (Spacelabs Healthcare Ltd, Hertford, UK) with Spacelabs Healthcare 2018 – Sentinel v11.0.0.9904 data processing software. All standard HRV parameters in the time and frequency domains were monitored.

In all subjects, standardized operative treatment was performed in the form of ETS by cutting the sympathetic chain at the level of R3 and R4 (ultrasound hook, R3, top and bottom – R4, top and bottom) and cutting the accessory Kuntz fibers. After the expert consensus from 2011, the term sympathicotomy was established for the cutting of sympathetic fibers, while the term sympathectomy means the removal of part of the sympathetic trunk [8]. Follow-up assessments were performed on the seventh day and one month after discharge from the hospital. One month after surgery, the presence and degree of CS were verified. Patients reported the presence of one of four offered degrees of CS: absent, minor, unpleasant or disabling.

Statistical methods

From the methods of descriptive statistics, the measures of central tendency were used in the study, specifically the arithmetic mean, measures of variability, namely the standard deviation and median, as well as relative numbers. From the methods of analytical statistics, methods for identifying empirical distributions (Kolmogorov–Smirnov test) were used, along with methods for assessing the significance of differences depending on the type of data and distribution, specifically the independent samples t-test, Mann–Whitney U test, and χ^2 test. To assess the significance of the relationship between predictor variables and outcome in relation to the time elapsed until the outcome, univariate and multivariate Cox regression analyses were used. The discriminatory capacity, i.e., the predictive accuracy of the examined parameters for the presence of CS, was determined by the area under the receiver operating characteristic (ROC) curve (c-statistic), and the best cut-off value of variables for predicting CS was also estimated. A c-statistic above 0.7 was considered an acceptable discriminative capacity of the model. Statistical data processing was performed in JASP software, version 0.96.0 (University of Amsterdam, Amsterdam, The Netherlands), and $p < 0.05$ was used as the criterion for statistical significance.

RESULTS

The study included 100 patients, aged 18–54 years, with an average age of 28.33 ± 8.51 years, a median age of 24 years (10/100), of whom 57 (57%) were female. There was no statistically significant difference in sex distribution in the observed groups PP and PPA PFH, $p = 0.162$.

CS was absent in 61 (61%) patients who were operated on ($p = 0.028$). Minor CS was most frequent ($p < 0.01$), and the incidence of unpleasant CS was higher than that of disabling CS ($p = 0.011$) (Figure 1).




Figure 1. Frequency of different degrees of postoperative compensatory sweating

Table 1. Mean patient age and gender and incidence of postoperative compensatory sweating in relation to type of primary focal hyperhidrosis

Parameters		Type of hyperhidrosis								p
		Palmar-plantar				Palmar-plantar-axillary				
		Mean	SD	N	%	Mean	SD	N	%	
Age (years)		29.18	8.73			27.48	8.27			0.320[a]
Sex	Male			30	52.6			27	47.4	0.545[b]
	Female			20	46.5			23	53.5	
Compensatory sweating	Absent			32	52.5			29	47.5	0.666[b]
	Minor			13	44.8			16	55.2	
	Unpleasant			5	55.6			4	44.4	
	Disabling			0	0			1	100	
Compensatory sweating	No			32	52.5			29	47.5	0.539[b]
	Yes			18	46.2			21	53.8	

SD – standard deviation;
[a]Mann–Whitney U-test;
[b]χ^2 test

Table 2. Mean values of the examined heart rate variability parameters in patients with and without compensatory sweating

Heart rate variability parameters	Compensatory sweating								p
	No				Yes				
	Mean	SD	Min	Max	Mean	SD	Min	Max	
HR maximum	127.7	19	85	173	121.3	16.8	92	162	0.088[c]
HR minimum	53.9	8.5	40	77	52.7	6.6	38	70	0.466[c]
HR	74.3	9.4	55	98	72.7	9.3	49	92	0.390[c]
SDNN (ms)	144.1	31.9	86.5	229.7	146.2	28.8	99.9	232.2	0.849[c]
NN (RR)	822.6	104	598	1072	842.9	114.9	649.4	1222.5	0.363[c]
SDANN	153.1	71.3	60.1	402.9	142.8	65.8	75.9	428.6	0.377[c]
RMSSD (ms)	53.2	51.2	21	412.7	55.2	30.6	23.5	151	0.283[c]
pNN50%	20.8	30.3	2.4	236.1	19.9	12.8	1.9	57.1	0.322[c]
LF (ms^2)	1290.6	721.8	298.4	4213.5	1519.4	1037.1	359.9	3951	0.621[c]
LF normalized	68.6	9.6	47	91.7	65.3	13.8	16.1	86.2	0.300[c]
HF	532.1	359.1	98.2	1466.1	945.8	1513.9	10.7	8585.5	0.276[c]
HF normalized	27.9	9.2	12.1	51.2	31.7	19.81	4	127.9	0.527[c]
LF/HF	2.9	1.4	1	6.7	2.7	1.42	0.8	7.1	0.334[c]

HR – heart rate; RR – relative risk; SDNN – standard deviation of normal RR intervals; NN – normal RR interval; SDANN – standard deviation of all average five-minute RR intervals; RMSSD – square root of the mean value of the square of the difference of successive RR intervals; pNN50% – the proportion of adjacent normal RR intervals that differ by more than 50 ms; LF – low-frequency range of heart rate variability; HF – high-frequency range of heart rate variability;
[c]independent samples t-test

Table 3. Mean age and frequency by sex in patients with and without compensatory sweating

Parameters		Compensatory sweating								p
		No				Yes				
	Mean	SD	N	%	Mean	SD	N	%		
Age (years)		25.61	6.6			32.59	9.45			< 0.01[a]
Sex	Male			35	61.4			22	38.6	0.924[b]
	Female			26	60.5			17	39.5	

[a]Mann–Whitney U test;
[b]χ^2 test

There were no statistically significant differences in the mean patient age ($p < 0.32$), or in sex distribution and the frequency of CS in relation to the type of PFH ($p > 0.05$) (Table 1).

There was no statistically significant difference in the mean values of the examined preoperative HRV parameters in patients with and without CS ($p > 0.05$) (Table 2).

Patients with CS were statistically significantly older ($p < 0.01$). There was no statistically significant difference in the sex distribution in patients with and without CS (Table 3).

In the group of patients with LF/HF < 2, there was no statistically significant difference in the mean values of preoperative LF/HF (1.59 *vs.* 1.44; p = 0.163), or in the group of patients with LF/HF ≥ 2 (3.41 *vs.* 3.5; p = 0.801). In the group of patients with PP PFH and LF/HF < 2, there was no statistically significant difference in mean LF/HF values (1.66 *vs.* 1.38; p = 0.078), or in the group of patients with LF/HF ≥ 2 (3.24 *vs.* 3.33; p = 0.851). In the group of patients with PPA PFH and LF/HF < 2, there was no statistically significant difference in the mean values of preoperative LF/HF (1.54 *vs.* 1.51; p = 0.876), or in the group of patients with LF/HF ≥ 2 (3.63 *vs.* 3.61; p = 0.974) (Figure 2).

Univariate Cox regression analysis showed that univariate statistically significant predictors of postoperative CS were age ($p < 0.01$) and HF after statistical control for age ($p < 0.01$) (Table 4).

Multivariate Cox regression analysis showed that age [relative risk (RR) 1.11; 95% confidence interval (CI) (1.05–1.18); $p < 0.01$] and HF before ETS [RR 1.00; 95% CI (1.00–1.001), $p < 0.01$] were independent predictors of CS. The analysis of ROC curves for the patient age variable showed that it has a statistically significant predictive accuracy for the occurrence of HF (area under the ROC curve 0.7333; 95% CI (0.634–0.833); $p < 0.01$), while it was not shown for HF. On that occasion, the best threshold value of the patient's age for predicting CS after ETS was determined, which is 23.5 years, with a combination of sensitivity 0.82 and specificity 0.47.

DISCUSSION

CS as the most frequent side effect of ETS was present in 39% of subjects (39/100), whereby it was characterized as unpleasant by 9% (9/100) and disabling by 1% (1/100). The literature reports a remarkably wide range in the prevalence of CS, varying from 3% to 98%. CS has been identified as the main culprit for patient dissatisfaction after ETS [4]. Such a large incidence range was a consequence of the unclassified nomenclature, as well as the definition of CS itself. In some studies, CS was reported exclusively when it reached incapacitating levels, while others documented even a minimal subjective feeling of increased sweating [5, 18, 19]. Many studies have indicated that the degree of CS is directly proportional to the height of the transection level of the sympathetic trunk, with a note that the degree of CS is the highest with R2 transection [18, 19]. Our study was designed so that all sympathetic chain transections were performed at the R3–R4 level precisely to avoid an increased incidence of CS.




Figure 2. Mean values of LF/HF ratio in groups according to the presence of compensatory sweating, in patients with different types of hyperhidrosis; LF – low-frequency range of heart rate variability; HF – high-frequency range of heart rate variability

Table 4. Univariate Cox regression for the prediction of compensatory sweating, controlled for age

Variable	RR	95% CI	p
Age (years)	1.11	1.05–1.18	< 0.01[d]
Gender	1.04	0.46–2.34	0.92[d]
HR maximum	0.99	0.97–1.01	0.32[d]
HR minimum	0.97	0.94–1.01	0.15[d]
HR	0.99	0.94–1.04	0.67[d]
SDNN (ms)	1.01	0.99–1.02	0.11[d]
SDNN (125–149) (ms)	2.307	0.99–5.71	0.07[d]
SDNN (> 150) pre (ms)	2.069	0.84–5.11	1.15[d]
NN (RR)	1.00	0.99–1.01	0.14[d]
SDANN	1.00	0.99–1.01	0.59[d]
RMSSD (ms)	0.82	0.99–1.01	0.82[d]
pNN50%	0.99	0.98–1.01	0.91[d]
LF (ms^2)	1.00	1.00–1.00	0.07[d]
LF normalized	0.98	0.96–1.01	0.23[d]
HF	1.00	1.00–1.01	< 0.01[d]
HF normalized	1.01	0.99–1.03	0.08[d]
LF/HF	0.97	0.75–1.23	0.77[d]

HR – heart rate; RR – relative risk; SDNN – standard deviation of normal RR intervals; NN – normal RR interval; SDANN – standard deviation of all average five-minute RR intervals; RMSSD – the square root of the mean value of the square of the difference of successive RR intervals; pNN50% – the proportion of adjacent normal RR intervals that differ by more than 50 ms; LF – low-frequency range of heart rate variability; HF – high-frequency range of heart rate variability; CI – confidence interval;
[d]univariate Cox regression

We believe that the degree of CS in our study is at a satisfactory level, which is primarily a consequence of the standardized operative technique, suitable selection of patients for ETS and detailed preoperative information provided to patients about potential side effects and complications. It is interesting that the only patient with a disabling form of CS was a 37-year-old male (recommended age for CS prevention is 25 years) and that he suffered from malaria in childhood.

An easily available, non-invasive predictor of CS would greatly improve patient selection and the success of ETS. Hyperstimulated sympathetic fibers responsible for sweating also partially innervate the heart. It makes sense to examine the potential use of HRV as a diagnostic method for the prediction of CS. There are three types of HRV measurement: ultrashort (under five minutes), short (five minutes), and 24-hour measurement. These measurements cannot be compared with each other due to different influences on the 24-hour measurement, which best reflects the real situation [20, 21]. This is why we have used the 24-hour measurement of HRV.

The LF/HF ratio has been proposed as an indicator of sympathovagal balance, with values of 0.5–2. Values over two units are considered a consequence of pathological SNS stimulation or parasympathetic nervous system (PNS) inactivity, while values below 0.5 are a consequence of pathological PNS stimulation [12, 20, 22]. We singled out LF/HF as a parameter to determine whether CS is more common in the group with sympathetic predominance (LF/HF ≥ 2). It was determined that there is no difference in the occurrence of CS in relation to LF/HF values. The difference did not exist even when this group was divided into PP and PPA PFH. The lowest measured value of LF/HF in our study was 0.9. Consequently, not a single patient had parasympathetic predominance, as expected, but all were either in balance or in the zone of sympathetic predominance.

After the analysis of the HRV parameters to predict the occurrence of CS, the existence of a statistically significant correlation of HF with CS was established. However, after ROC curve testing, significance was not obtained. We identified only two studies that correlated HRV and CS. Hyun et al. [23] do not report any HRV parameter as a possible predictor of CS. Tiwari et al. [24] report HF as a positive predictive factor for CS. Unlike our study, HF prediction was not tested on ROC curves. Both studies were performed with five-minute HRV recordings, which is a major limitation.

Although none of the HRV parameters in our study can be used to predict CS, we confirmed that CS is correlated with age and that patients below 23 years of age have a lower probability of CS. In current recommendations, an age below 25 years is considered appropriate for ETS [3, 5, 8].

CONCLUSION

HRV parameters cannot be used as predictors for the occurrence of CS after bilateral thoracoscopic sympathicotomy in persons suffering from PFH. Although the HF parameter was singled out in our study as a potential predictive factor, after ROC curve testing, significance was not obtained. Our study confirmed that the optimal age at which to perform bilateral thoracoscopic sympathicotomy is below 25 years, more precisely below 23.5 years.

Ethics: The study was approved by the Ethics Commission of the Institute for Pulmonary Diseases of Vojvodina under the number 6-VI/1 on December 9, 2021, and was conducted in accordance with the principles of the Declaration of Helsinki.

Conflict of interest: None declared.

REFERENCES

1. Wohlrab J, Bechara FG, Schick C, Naumann M. Hyperhidrosis: a central nervous dysfunction of sweat secretion. Dermatol Ther (Heidelb). 2023;13(2):453–63. [DOI: 10.1007/s13555-022-00885-w] [PMID: 36627476]
2. Bovell DL, Clunes MT, Elder HY, Milsom J, McEwan Jenkinson D. Ultrastructure of the hyperhidrotic eccrine sweat gland. Br J Dermatol. 2001;145(2):298–301. [DOI: 10.1046/j.1365-2133.2001.04351.x] [PMID: 11531796]
3. Wang Y, Jiang W, Chen H, Zhou H, Liu Z, Liu Z, et al. Sympathetic nervous system mediates cardiac remodeling after myocardial infarction in a circadian disruption model. Front Cardiovasc Med. 2021;8:668387. [DOI: 10.3389/fcvm.2021.668387] [PMID: 33842566]
4. Liu Y, Weng W, Tu Y, Wang J, Chinese Expert Committee on Palmar Hyperhidrosis. Chinese expert consensus on the surgical treatment of primary palmar hyperhidrosis (2021 version). Chin Med J (Engl). 2022;135(11):1264–71. [DOI: 10.1097/CM9.0000000000002198] [PMID: 35830261]
5. Santos TS, Bachichi TG, Joaquim DT, De Sousa MH, Vieira Ponte E, De Campos JRM, et al. Compensatory sweating after thoracoscopic sympathectomy for primary focal hyperhidrosis: a series of 820 cases. Interdiscip Cardiovasc Thorac Surg. 2025;40(3):ivaf063. [DOI: 10.1093/icvts/ivaf063] [PMID: 40080705]
6. Henning MAS, Barati F, Jemec GBE. A systematic review and meta-analysis of psychiatric diseases in individuals with primary hyperhidrosis. Clin Exp Dermatol. 2025;50(2):323–30. [DOI: 10.1093/ced/llae389] [PMID: 39351777]
7. Glas B, Stachurska M, Dunford LJ, Shayesteh A. Food and beverage habits among individuals with primary hyperhidrosis: a case-control survey in Sweden. Clin Cosmet Investig Dermatol. 2025;18:2769–76. [DOI: 10.2147/CCID.S547497] [PMID: 41164747]
8. Vannucci F, Araújo JA. Thoracic sympathectomy for hyperhidrosis: from surgical indications to clinical results. J Thorac Dis. 2017;9(Suppl 3):S178–S192. [DOI: 10.21037/jtd.2017.04.04] [PMID: 28446983]
9. Cerfolio RJ, De Campos JRM, Bryant AS, Connery CP, Miller DL, DeCamp MM, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg. 2011;91(5):1642–8. [DOI: 10.1016/j.athoracsur.2011.01.105] [PMID: 21524489]
10. Shi C, Chen Z, Zhang L, Zhang X, Liang X, Yan L, et al. Sweat components as a promising monitoring tool for systemic diseases. J Physiol Sci. 2026;76(2):100068. [DOI: 10.1016/j.jphyss.2026.100068] [PMID: 41856079]
11. Patsy M, Ge K, Khodabukus A, Bursac N. Development and modeling of cardiac autonomic innervation. Nat Cardiovasc Res. 2025;4(12):1598–615. [DOI: 10.1038/s44161-025-00746-7] [PMID: 41350484]
12. Li YL. Stellate ganglia and cardiac sympathetic overactivation in heart failure. Int J Mol Sci. 2022;23(21):13311. [DOI: 10.3390/ijms232113311] [PMID: 36362099]
13. Henning MAS, Barati F, Jemec GBE. Quality of life in individuals with primary hyperhidrosis: a systematic review and meta-analysis. Clin Auton Res. 2023;33(4):519–28. [DOI: 10.1007/s10286-023-00954-w] [PMID: 37507605]
14. Abusailik MA, Mustafa SMB, Alzboun HM, Al-Issa HA, Oweis SW, Alshudeifat AY, et al. Primary hyperhidrosis: prevalence, severity, and impact on quality of life among Jordanian patients. Indian J Dermatol. 2021;66(5):573. [DOI: 10.4103/ijd.ijd_812_20] [PMID: 35068527]
15. Lima SO, Neto JM, Fontes LM, Galrão de Almeida Figueiredo MB, Santos JM, Santana VR. Evaluation of quality of life (QOL) of young patients with primary hyperhidrosis (PH) before and after endoscopic thoracic sympathectomy (ETS). J Am Acad Dermatol. 2023;88(5):e197-e201. [DOI: 10.1016/j.jaad.2015.10.048] [PMID: 37069802]
16. Ureña A, Grando L, Rodriguez-Gussinyer L, Macía I, Rivas F, Quiroga NI, et al. 20-year efficacy of endoscopic thoracic sympathectomy for primary hyperhidrosis: a cohort study. J Clin Med. 2025;14(14):4831. [DOI: 10.3390/jcm14144831] [PMID: 40725520]
17. Ergelašev I, Kuhajda I, Galić M, Lalić N, Bojović M. Evaluation of the quality of life 10 years after bilateral thoracoscopic sympathicotomy in subjects with primary focal hyperhidrosis. Srp Arh Celok Lek. 2024;152(7–8):363–7. [DOI: 10.2298/SARH240524053E]
18. Kaya D, Karaca S, Barutcu I, Esen AM, Kulac M, Esen O. Heart rate variability in patients with essential hyperhidrosis: dynamic influence of sympathetic and parasympathetic maneuvers. Ann Noninvasive Electrocardiol. 2005;10(1):1–6. [DOI: 10.1111/j.1542-474X.2005.00578.x] [PMID: 15649231]
19. Ishy A, de Campos JRM, Wolosker N, Kauffman P, Tedde ML, Chiavoni CR, et al. Objective evaluation of patients with palmar hyperhidrosis submitted to two levels of sympathectomy: T3 and T4. Interact Cardiovasc Thorac Surg. 2011;12(4):545–9. [DOI: 10.1510/icvts.2010.252015] [PMID: 21233258]
20. Yang J, Tan JJ, Ye GL, Gu WQ, Wang J, Liu YG. T3/T4 thoracic sympathictomy and compensatory sweating in treatment of palmar hyperhidrosis. Chin Med J (Engl). 2007;120(18):1574–7. [DOI: 10.1097/00029330-200709020-00003] [PMID: 17908472]
21. Shaffer F, Ginsberg JP. An overview of heart rate variability metrics and norms. Front Public Health. 2017;5:258. [DOI: 10.3389/fpubh.2017.00258] [PMID: 29034226]
22. Yılmaz M, Kayançiçek H, Çekici Y. Heart rate variability: highlights from hidden signals. J Integr Cardiol. 2018;4(5):1–8. [DOI: 10.15761/JIC.1000258]
23. Hyun KY, Kim JJ, Im KS, Lee BS, Kim YJ. Machine learning analysis of primary hyperhidrosis for classification of hyperhidrosis type and prediction of compensatory hyperhidrosis. J Thorac Dis. 2023;15(9):4808–17. [DOI: 10.21037/jtd-23-471] [PMID: 37868857]
24. Tiwari R, Kumar R, Malik S, Raj T, Kumar P. Analysis of heart rate variability and implication of different factors on heart rate variability. Curr Cardiol Rev. 2021;17(5):e160721189770. [DOI: 10.2174/1573403X16999201231203854] [PMID: 33390146]

Да ли се варијабилност срчане фреквенције може користити за предвиђање компензаторног знојења након ендоскопске торакалне симпатикотомије код болесника са примарном фокалном хиперхидрозом?

Иван Ергелашев[1,2], Иван Кухајда[1,2], Стефан Андрић[3], Сања Ергелашев[3], Александра Вулин[1,3], Синиша Максимовић[1,2], Срђан Гавриловић[1,4], Урош Батрановић[4], Марко Бојовић[1,5], Ненси Лалић[1,6]

[1]Универзитет у Новом Саду, Медицински факултет, Нови Сад, Србија;
[2]Институт за плућне болести Војводине, Клиника за грудну хирургију, Нови Сад – Сремска Каменица, Србија;
[3]Институт за кардиоваскуларне болести Војводине, Клиника за кардиологију, Нови Сад – Сремска Каменица, Србија;
[4]Институт за плућне болести Војводине, Клиника за ургентну пулмологију, Нови Сад – Сремска Каменица, Србија;
[5]Институт за онкологију Војводине, Клиника за радијациону онкологију, Нови Сад – Сремска Каменица, Србија;
[6]Институт за плућне болести Војводине, Клиника за плућну онкологију, Нови Сад – Сремска Каменица, Србија

САЖЕТАК

Увод/Циљ Хиперхидроза је стање патолошког прекомерног знојења које превазилази физиолошке потребе организма за терморегулацијом. Ендоскопска торакална симпатикотомија (ЕТС) представља уобичајен начин лечења примарне фокалне хиперхидрозе (ПФХ), али може довести до појаве компензаторног знојења (КЗ), које представља њену најчешћу постоперативну компликацију. Циљ ове студије био је да се испита да ли параметри варијабилности срчане фреквенције могу предвидети појаву КЗ.

Методе Спроведена је проспективна једноцентрична студија која је обухватила 100 болесника са ПФХ који су подвргнути ЕТС. Преоперативно је код свих болесника урађен 24-часовни холтер ЕКГ ради процене стандардних параметара варијабилности срчане фреквенције. ЕТС је изведена пресецањем симпатичког ланца на нивоу трећег (*R*3) и четвртог ребра (*R*4), укључујући и помоћна Кунцова влакна. Месец дана након операције процењивани су присуство и степен КЗ.

Резултати КЗ није било присутно код 61% болесника ($p = 0,028$). Благо КЗ било је најчешћи облик ($p < 0,01$). Није утврђена статистички значајна разлика у анализираним преоперативним параметрима варијабилности срчане фреквенције између болесника са КЗ и без њега ($p > 0,05$), укључујући категорије односа *LF/HF*, које представљају уравнотежену аутономну активност (*LF/HF* < 2) и симпатичку доминацију (*LF/HF* ≥ 2). Анализа *ROC* криве показала је да старост има статистички значајну предиктивну тачност за појаву КЗ (*AUC* 0,7333; 95% *CI* 0,634–0,833; $p < 0,01$), са оптималном граничном вредношћу од 23,5 година (сензитивност 0,82; специфичност 0,47).

Закључак Параметри варијабилности срчане фреквенције не могу поуздано предвидети појаву КЗ након билатералне ЕТС код болесника са ПФХ. Студија је потврдила да је оптимална старост за извођење операције испод 23,5 године.

Кључне речи: видео-асистирана торакална хирургија; знојење; симпатектомија; аутономни нервни систем; минимално инвазивна хирургија